Altering cancer transcriptomes using epigenomic inhibitors

BACKGROUND: Due to the hyper-activation of WNT signaling in a variety of cancer types, there has been a strong drive to develop pathway-specific inhibitors with the eventual goal of providing a chemotherapeutic antagonist of WNT signaling to cancer patients. A new category of drugs, called epigeneti...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaddis, Malaina, Gerrard, Diana, Frietze, Seth, Farnham, Peggy J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506402/
https://www.ncbi.nlm.nih.gov/pubmed/26191083
http://dx.doi.org/10.1186/1756-8935-8-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506402/
https://www.ncbi.nlm.nih.gov/pubmed/26191083
http://dx.doi.org/10.1186/1756-8935-8-9

Ejemplares similares